OmicsBank Secures $2.25M from Redesign Health to Scale Global Multi-Omics Data Infrastructure
OmicsBankCompany
Redesign HealthInvestor
OmicsBank announced a $2.25 million seed round led by Redesign Health on August 25, 2026. The capital will fund the expansion of its multi‑omics data infrastructure across hospitals in South Asia, Southeast Asia and the Middle East, adding to a network that already spans 90+ institutions and 12.5 million patient records.
OmicsBank secured $2.25 million in seed financing from Redesign Health, marking the latest infusion of capital for the clinical data infrastructure startup. The round, closed on August 25, 2026, positions the company to scale its multi‑omics platform beyond its current footprint of 90+ hospitals and diagnostic labs across South Asia, Southeast Asia and the Middle East.
Deal Terms
The seed round was fully subscribed by Redesign Health, a global venture capital and applied‑technology firm. No valuation or revenue multiple was disclosed. The funding will be allocated to deepen integration with hospital firewalls, expand the de‑identification pipeline, and accelerate go‑to‑market efforts in additional regions, including the United States.
Background
Founded in 2025 by serial entrepreneurs Sumit Sinha and Vijay Goel, OmicsBank tackles a persistent bias in life‑science AI: under‑representation of Asian populations in genomic and clinical datasets. The platform currently aggregates 12.5 million longitudinal electronic health records, more than 30 million DICOM images, 6 million pathology slides, and 500,000 whole‑genome and multi‑omics profiles. Data are standardized at the source into FHIR and OMOP CDM formats, enabling tokenized, GPU‑ready datasets for AI developers and real‑world evidence for pharma sponsors.
The company’s approach differs from centralized data lakes by deploying software behind hospital firewalls, ensuring compliance with local IRB, HIPAA and GDPR rules while maintaining data sovereignty. This architecture has earned the trust of institutions that are traditionally cautious about external data sharing.
Redesign Health’s Head of Ventures, Neil Patel, highlighted the founders’ operational pedigree as the primary investment catalyst, noting that the team has built five prior companies and understands the nuances of earning hospital trust. Sumit Sinha emphasized the strategic imperative of diversifying the data foundation for drug development and healthcare AI, pointing to the opportunity to connect Asian datasets with global health systems.
The infusion of seed capital arrives as the broader AI‑driven health tech sector intensifies its search for high‑quality, diverse clinical data. OmicsBank’s model—software‑as‑a‑service (SaaS) that monetizes data access and compute environments—places it at the intersection of data infrastructure, AI enablement, and pharmaceutical research.
Why It Matters
For OmicsBank, the Redesign Health investment validates its SaaS‑based data‑infrastructure model and provides the runway to deepen hospital partnerships in regions where data scarcity has limited AI research. The capital will enable faster rollout of its de‑identification and standardization engine, strengthening its competitive moat against larger data aggregators that rely on centralized repositories.
Competitors that depend on bulk data acquisition without on‑premise processing may find it harder to match OmicsBank’s compliance‑first, hospital‑centric approach. As the startup expands into the U.S., existing regional players will need to either partner with similar on‑site platforms or risk losing access to the increasingly valuable Asian patient cohorts that OmicsBank curates.
Key Points
- OmicsBank raised $2.25 million in a seed round led by Redesign Health
- The platform currently covers 12.5 million patient records, 30 million+ DICOM images, 6 million pathology slides, and 500,000 multi‑omics profiles
- OmicsBank’s software runs behind hospital firewalls, standardizing data into FHIR and OMOP CDM formats
- The funding will support expansion into additional markets, including the United States
- Redesign Health cited the founders’ track record of building five prior companies as a key investment rationale
Analysis
OmicsBank’s seed raise arrives at a moment when AI‑driven drug discovery and clinical decision support are constrained by limited, non‑representative data. By embedding its SaaS platform within hospital firewalls, the company sidesteps the regulatory friction that hampers centralized data lakes, offering a compliance‑ready pipeline that can be monetized through subscription fees for data access and compute credits. Although the round’s valuation was not disclosed, the $2.25 million infusion signals investor confidence in a recurring‑revenue model built on data licensing and platform usage. As biotech firms and AI startups increasingly target diverse genomic cohorts, OmicsBank’s multi‑omics footprint—spanning genomics, proteomics and metabolomics—positions it to command premium pricing for tokenized datasets. The expansion into the U.S. market could unlock cross‑regional cohort studies, further differentiating the platform from generic data brokers. For SaaS investors, the deal underscores the growing appetite for niche infrastructure plays that combine regulatory compliance, data standardization and AI enablement, suggesting that similar models in other therapeutic verticals may attract comparable capital as the demand for high‑quality clinical data intensifies.